Clinical trials: Uterine Corpus Leiomyosarcoma
Uterine Leiomyosarcoma
Letrozole in Uterine Leiomyosarcoma
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
- Trial name
- NCT05649956
- Testing
- Letrozole
- Where
- 34 sites in United States
- Volunteers
- 40 people
- Sponsor
- GOG Foundation
Endometrial Cancer, Fallopian Tube Cancer
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003334
- Testing
- paclitaxel, pegylated liposomal doxorubicin hydrochloride
- Where
- 5 sites in United States
- Sponsor
- NYU Langone Health
Endometrial Cancer, Sarcoma
Thalidomide in Treating Patients With Gynecologic Sarcomas
RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent…
- Trial name
- NCT00006005
- Testing
- thalidomide
- Where
- 10 sites in United States
- Sponsor
- New York University Cancer Institute
Endometrial Cancer, Ovarian Cancer
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003718
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
This phase II/III trial compares the effect of the combination treatment with olaparib and temozolomide to trabectedin or pazopanib (two of the most common chemotherapy drugs used as usual approach) in patients with uterine…
- Conditions
- Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Trial name
- NCT05432791
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 145 sites in United States, Puerto Rico
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Sarcoma, Uterine Leiomyosarcoma
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas.
- Conditions
- Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS
- Trial name
- NCT07467772
- Testing
- Elacestrant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
This phase II trial is studying how well sunitinib works in treating patients with recurrent or persistent leiomyosarcoma of the uterus.
- Trial name
- NCT00378911
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Stromal Sarcoma, Adenosarcoma of Uterus
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
This phase 2 clinical trial aims to evaluate the efficacy of Fulvestrant, an ER-antagonist, in women with estrogen receptor positive (ER+) low-grade gynecological cancers.
- Conditions
- Endometrial Stromal Sarcoma, Adenosarcoma of Uterus, Leiomyosarcoma Uterus, Endometrial Cancer
- Trial name
- FUCHSia (NCT03926936)
- Testing
- Fulvestrant
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 17 people
- Sponsor
- Frederic Amant
Sarcoma
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00041236
- Testing
- exatecan mesylate
- Where
- 10 sites in Belgium, Denmark and 2 more
- Volunteers
- 39 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult Fibrosarcoma, Adult Leiomyosarcoma
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
This phase II trial is studying how well AZD0530 works in treating patients with recurrent locally advanced, or metastatic soft tissue sarcoma.
- Conditions
- Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00659360
- Testing
- saracatinib
- Where
- 4 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
This phase II trial studies olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma
- Trial name
- NCT03880019
- Testing
- Computed Tomography, Core Biopsy, Magnetic Resonance Imaging
- Where
- 15 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227669
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 32 sites in France
- Volunteers
- 90 people
- Sponsor
- UNICANCER
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Sarcoma
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00003054
- Testing
- paclitaxel
- Where
- 65 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Sarcoma
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
RATIONALE: Drugs used in chemotherapy, such as docetaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00101127
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Where
- 60 sites in United States
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Female Reproductive Cancer
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
This phase II trial is studying how well ziv-aflibercept works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma.
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma
- Trial name
- NCT00390234
- Testing
- ziv-aflibercept
- Where
- 16 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma of the uterus that has come back or persistent.
- Trial name
- NCT01637961
- Testing
- Alisertib, Laboratory Biomarker Analysis
- Where
- 50 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients with recurrent or…
- Trial name
- NCT00003316
- Testing
- gemcitabine hydrochloride
- Where
- 40 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer, Sarcoma
Chemotherapy in Treating Patients With Sarcoma of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients who have…
- Trial name
- NCT00005643
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 49 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group